A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas

被引:38
作者
Chai, Rui-Chao [1 ,2 ]
Liu, Yu-Qing [1 ,2 ]
Zhang, Ke-Nan [1 ,2 ,3 ]
Wu, Fan [1 ,2 ]
Zhao, Zheng [1 ,2 ]
Wang, Kuan-Yu [1 ,2 ,3 ]
Jiang, Tao [1 ,2 ,3 ]
Wang, Yong-Zhi [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Neurosurg Inst, Dept Mol Neuropathol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China
[3] Chinese Glioma Genome Atlas, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
GENE PROMOTER METHYLATION; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; CUTOFF VALUE; CPG ISLAND; GLIOBLASTOMA; TEMOZOLOMIDE; ASSAY; SIGNATURE; SURVIVAL; BENEFIT;
D O I
10.1038/s41379-018-0143-2
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The methylation status of the promoter of MGMT gene is a crucial factor influencing clinical decision-making in patients with gliomas. MGMT pyrosequencing results are often dichotomized by a cut-off value based on an average of several tested CpGs. However, this method frequently results in a "gray zone", representing a dilemma for physicians. We therefore propose a novel analytical model for MGMT methylation pyrosequencing. MGMT CpG heterogeneity was investigated in 213 glioma patients in two tested cohorts: cohort A in which CpGs 75-82 were tested and cohort B in which CpGs 72-78 were tested. The predictive performances of the novel and traditional averaging models were compared in 135 patients who received temozolomide using receiver operating characteristic curves and Kaplan-Meier curves, and in patients stratified according to isocitrate dehydrogenase gene mutation status. The results were validated in an independent cohort of 65 consecutive patients with high-grade gliomas from the Chinese Glioma Genome Atlas database. Heterogeneity of MGMT promoter CpG methylation level was observed in most gliomas. The optimal cut-off value for each individual CpG varied from 4-16%. The current analysis defined MGMT promoter methylation as occurring when at least three CpGs exceeded their respective cut-off values. This novel analysis could accurately predict the prognosis of patients in the methylation "gray zone" according to the standard averaging method, and improved the area under the curves from 0.67, 0.76, and 0.67 to 0.70, 0.84, and 0.72 in cohorts A, B, and the validation cohort, respectively, demonstrating superiority of this analytical method in all three cohorts. Furthermore, the advantages of the novel analysis were retained regardless of WHO grade and isocitrate dehydrogenase gene mutation status. In conclusion, this novel analytical model offers an improved clinical predictive performance for MGMT pyrosequencing results and is suitable for clinical use in patients with gliomas.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 43 条
[11]   Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma [J].
Christians, Arne ;
Hartmann, Christian ;
Benner, Axel ;
Meyer, Jochen ;
von Deimling, Andreas ;
Weller, Michael ;
Wick, Wolfgang ;
Weiler, Markus .
PLOS ONE, 2012, 7 (03)
[12]   Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy [J].
Dunn, J. ;
Baborie, A. ;
Alam, F. ;
Joyce, K. ;
Moxham, M. ;
Sibson, R. ;
Crooks, D. ;
Husband, D. ;
Shenoy, A. ;
Brodbelt, A. ;
Wong, H. ;
Liloglou, T. ;
Haylock, B. ;
Walker, C. .
BRITISH JOURNAL OF CANCER, 2009, 101 (01) :124-131
[13]   MethyLight: a high-throughput assay to measure DNA methylation [J].
Eads, Cindy A. ;
Danenberg, Kathleen D. ;
Kawakami, Kazuyuki ;
Saltz, Leonard B. ;
Blake, Corey ;
Shibata, Darryl ;
Danenberg, Peter V. ;
Laird, Peter W. .
NUCLEIC ACIDS RESEARCH, 2000, 28 (08) :32
[14]   Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].
Esteller, M ;
Garcia-Foncillas, J ;
Andion, E ;
Goodman, SN ;
Hidalgo, OF ;
Vanaclocha, V ;
Baylin, SB ;
Herman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354
[15]   Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients [J].
Felsberg, Joerg ;
Rapp, Marion ;
Loeser, Simon ;
Fimmers, Rolf ;
Stummer, Walter ;
Goeppert, Matthias ;
Steiger, Hans-Jacob ;
Friedensdorf, Britta ;
Reifenberger, Guido ;
Sabel, Michael C. .
CLINICAL CANCER RESEARCH, 2009, 15 (21) :6683-6693
[16]   MGMT: Its role in cancer aetiology and cancer therapeutics [J].
Gerson, SL .
NATURE REVIEWS CANCER, 2004, 4 (04) :296-307
[17]   Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide [J].
Hegi, ME ;
Diserens, AC ;
Godard, S ;
Dietrich, PY ;
Regli, L ;
Ostermann, S ;
Otten, P ;
Van Melle, G ;
de Tribolet, N ;
Stupp, R .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :1871-1874
[18]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[19]   Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands [J].
Herman, JG ;
Graff, JR ;
Myohanen, S ;
Nelkin, BD ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9821-9826
[20]   Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 [J].
Herrlinger, Ulrich ;
Rieger, Johannes ;
Koch, Dorothee ;
Loeser, Simon ;
Blaschke, Britta ;
Kortmann, Rolf-Dieter ;
Steinbach, Joachim P. ;
Hundsberger, Thomas ;
Wick, Wolfgang ;
Meyermann, Richard ;
Tan, Ta-Chih ;
Sommer, Clemens ;
Bamberg, Michael ;
Reifenberger, Guido ;
Weller, Michael .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4412-4417